<SEC-DOCUMENT>0001062822-20-000073.txt : 20201117
<SEC-HEADER>0001062822-20-000073.hdr.sgml : 20201117
<ACCEPTANCE-DATETIME>20201117072220
ACCESSION NUMBER:		0001062822-20-000073
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201117
DATE AS OF CHANGE:		20201117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		201319259

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20201116.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620,d:453bde7f71df427290e450f527146d39--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20201116</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV80L2ZyYWc6YWZhYTBjN2M5YTFhNDVkY2ExYzYyMDcyYTA5Zjk1Y2IvdGFibGU6ZDk3ZDVlNTVjMzc5NGRlYWIyZThmMWM5ZGE3OGVlNmIvdGFibGVyYW5nZTpkOTdkNWU1NWMzNzk0ZGVhYjJlOGYxYzlkYTc4ZWU2Yl8wLTEtMS0xLTA_0867a43a-b53a-492d-a86a-4c73e3d42542">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV80L2ZyYWc6YWZhYTBjN2M5YTFhNDVkY2ExYzYyMDcyYTA5Zjk1Y2IvdGFibGU6ZDk3ZDVlNTVjMzc5NGRlYWIyZThmMWM5ZGE3OGVlNmIvdGFibGVyYW5nZTpkOTdkNWU1NWMzNzk0ZGVhYjJlOGYxYzlkYTc4ZWU2Yl8xLTEtMS0xLTA_a86286a4-3764-46dd-a8b1-4576c790ff8b">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20201116.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i270954990545440a902712dda84cdeec_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i453bde7f71df427290e450f527146d39_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjkx_560d42dd-6488-48d6-b041-da9b37ee7ac9">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8yNjY_ba3f57e2-8ae0-488a-8721-228fe7cba944">November 16, 2020</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjky_c1ede87c-7b6a-497b-8160-af3c5b590da5">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTAtMS0xLTA_d2bb0705-c6f9-46e1-a344-2f749130d75f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTEtMS0xLTA_6c6d9301-ef79-41ab-99cf-6b48bffdc2c9">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTItMS0xLTA_9f0c9b50-61df-4329-8cea-f5a4e8428575">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg1_ebd96192-3e18-4b07-b6b0-dab37ca09b77">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg2_9ec94ff4-b6c0-4fa6-bbb4-b94fa4977cd4">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjkz_1617e7d5-f86d-434b-b1ae-a49b233cc8b5">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV80MDk_d3b7ee8c-c1a1-45d2-a5cd-d39f187e1204">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV80Njg_3c94bedd-654e-4e0b-b8e9-27d123e4f18b">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjk0_b0dbb7ca-e455-4322-9b94-d3983e7ece3c">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTAtMS0xLTA_ec20cf52-4154-4888-a186-dcd2b359f49a">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTEtMS0xLTA_44694ecd-aada-45ed-92b5-a092c38aec01">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTItMS0xLTA_20932a4f-fb53-425a-8b57-25df14ae579a">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg3_7d6b4e36-2548-4150-bf02-3e49550d24ac">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjgw_f41177fe-3143-4f33-8989-5e1e77d5e5af">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg0_27abc27c-9d56-4670-85e7-075e454c1cb7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg5_e55c2392-4c60-4978-805c-9a205b5730ec">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjgy_5fb20628-e5b2-46c6-ac39-e9bbbfd91e22">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i453bde7f71df427290e450f527146d39_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 16, 2020, we issued a press release announcing results from our SCORED and SOLOIST Phase 3 clinical trials of sotagliflozin, the presentation of such results at the American Heart Association Scientific Sessions 2020 and the publication of such results in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated herein by this reference.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div id="i453bde7f71df427290e450f527146d39_99"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseahasotagli.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated November 16, 2020</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i453bde7f71df427290e450f527146d39_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:52.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   November 17, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i453bde7f71df427290e450f527146d39_105"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.304%"><tr><td style="width:1.0%"></td><td style="width:8.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseahasotagli.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated November 16, 2020</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseahasotagli.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5bee3fa2329b4e88a2fd97a63174cc6c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESULTS FROM SOLOIST AND SCORED OUTCOMES STUDIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRESENTED AT LATE-BREAKING SCIENCE SESSION OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The Woodlands, Texas, November 16, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - Lexicon Pharmaceuticals, Inc. (Nasdaq&#58; LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p&#60;0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure.  In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p&#60;0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml&#47;minute per 1.73 m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of body-surface area.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine (NEJM) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in two separate articles titled&#58; &#8220;Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure&#8221; and &#8220;Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.&#8221;  The articles may be accessed at www.nejm.org.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,&#8221; said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results.  &#8220;SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).  SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk.  Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Key SOLOIST Phase 3 Study Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure.  The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients starting treatment with 200 mg sotagliflozin </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">once daily compared with placebo, with dosing initiated either before or within 3 days of hospital discharge.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The first dose of sotagliflozin or placebo was administered prior to hospital discharge in 48.8% of the patients and a median of two days after discharge in 51.2% of the patients, with the benefits of sotagliflozin being consistent between those prespecified subgroups of patients.  The initial 200 mg once daily dose of sotagliflozin was increased to 400 mg once daily if unacceptable side effects did not occur.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Treatment with sotagliflozin resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo.  A total of 600 primary endpoint events occurred in the study, with 245 events in the sotagliflozin treated group and 355 events in the placebo group.  There were 51.0 primary endpoint events per 100 patient-years in the sotagliflozin treated group as compared to 76.3 events per 100 patient-years in the placebo group (HR&#61;0.67&#59; 95% confidence interval &#91;CI&#93;&#61;0.52 to 0.85&#59; p&#60;0.001).  There were 10.6 events of cardiovascular death per 100 patient-years in the sotagliflozin treated group as compared to 12.5 events per 100 patient-years in the placebo group (HR&#61;0.84&#59; 95% CI&#61;0.58 to 1.22&#59; p&#61;0.36).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Of note, effects on the primary endpoint were consistent among patients suffering from heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), with a hazard ratio of 0.72 (95% CI&#61;0.56 to 0.94) in patients with a left ventricular ejection fraction (LVEF) of less than 50% and a hazard ratio of 0.48 (95% CI&#61;0.27 to 0.86) in patients with a LVEF of greater than or equal to 50%.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 3.0% (n&#61;18) of the patients in the sotagliflozin treated group and in 2.8% (n&#61;17) of the patients in the placebo group.  Based on investigator reported events, the most common adverse events of special interest included hypotension (6.0% on sotagliflozin versus 4.6% on placebo), urinary tract infections (4.8% on sotagliflozin versus 5.1% on placebo), acute kidney injury (4.1% on sotagliflozin versus 4.4% on placebo), and diarrhea (6.1% on sotagliflozin versus 3.4% on placebo).  Among other adverse events of interest, in SOLOIST, genital mycotic infections (0.8% on sotagliflozin vs. 0.2% on placebo) were infrequent, severe hypoglycemia (1.5% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin treated group and diabetic ketoacidosis (0.3% on sotagliflozin vs. 0.7% on placebo) was similar between treatment groups.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The SOLOIST study was originally designed with a primary endpoint of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, as determined by independent adjudication, but was modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study-group assignments and without information from an interim analysis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The results for first occurrence of cardiovascular death or hospitalization for heart failure (HR&#61;0.71&#59; 95% CI&#61;0.57 to 0.89&#59; p&#61;0.003) based on investigator reported events were consistent with those of the modified primary endpoint.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Key SCORED Phase 3 Study Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of body-surface area, and risks for cardiovascular disease.  The primary endpoint was the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.  The initial 200 mg once daily dose of sotagliflozin was increased to 400 mg once daily if unacceptable side effects did not occur.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Treatment with sotagliflozin resulted in a significantly lower total number of cardiovascular deaths, heart failure hospitalizations and urgent visits as compared to placebo.  A total of 930 primary endpoint events occurred in the study, with 400 events in the sotagliflozin treated group and 530 events in the placebo group.  There were 5.6 primary endpoint events per 100 patient-years in the sotagliflozin treated group as compared to 7.5 events per 100 patient-years in the placebo group (HR&#61;0.74&#59; 95% CI&#61;0.63 to 0.88&#59; p&#60;0.001).  There were 2.2 events of cardiovascular death per 100 patient-years in the sotagliflozin treated group as compared to 2.4 events per 100 patient-years in the placebo group (HR&#61;0.90&#59; 95% CI&#61;0.73 to 1.12&#59; p&#61;0.35).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Of note, over the course of the study, the data showed an average reduction in hemoglobin A1c of 0.56% in the sotagliflozin treated group as compared to a reduction of 0.25% in the placebo group in patients with severe chronic kidney disease, eGFR less than 30 ml per minute per 1.73 m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of body-surface area (p&#60;0.001).  In patients with moderate chronic kidney disease, eGFR greater than or equal to 30 ml per minute per 1.73 m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of body-surface area, the data showed an average reduction in hemoglobin A1c of 0.60% in the sotagliflozin treated group as compared to a reduction of 0.17% in the placebo group (p&#60;0.001).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Serious adverse events that led to discontinuation of study drug, as determined by investigators, occurred in 2.1% (n&#61;112) of the patients in the sotagliflozin treated group and in 1.8% (n&#61;94) of the patients in the placebo group.  Based on investigator reported events, the most common adverse events of special interest included urinary tract infections (11.5% on sotagliflozin versus 11.1% on placebo), diarrhea (8.5% on sotagliflozin versus 6.0% on placebo), volume depletion (5.3% on sotagliflozin versus 4.0% on placebo), bone fractures (2.1% on sotagliflozin versus 2.2% on placebo), and genital mycotic infections (2.4% on sotagliflozin versus 0.9% on placebo).  Among other adverse events of interest, diabetic ketoacidosis (0.6% on sotagliflozin vs. 0.3% on placebo) was more common in the sotagliflozin treated group and severe hypoglycemia (1.0% on sotagliflozin vs. 1.0% on placebo) was similar between treatment groups.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The SCORED study was originally designed with co-primary endpoints, assessed in time-to-event analyses, of the first occurrence of a major adverse cardiovascular event (defined as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, or 3-point MACE) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure, as determined by independent adjudication, but were modified in connection with the early close out of the study to include urgent heart failure visits and reflect the total number of events, as determined by investigators, in order to enhance the statistical power of the comparison.  The specification of the primary endpoint based on total events was implemented without any awareness of the study outcomes or study-group assignments and without information from an interim analysis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In a time-to-event analysis, applying the original co-primary endpoints based on investigator reported events, the results for both the first occurrence of a MACE event (HR&#61;0.84&#59; 95% CI&#61;0.72 to 0.99&#59; p&#61;0.035) and the first occurrence of death from cardiovascular causes or hospitalization for heart failure (HR&#61;0.78&#59; 95% CI&#61;0.66 to 0.91&#59; p&#61;0.001) were consistent with those of the modified primary endpoint.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Sotagliflozin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Discovered using Lexicon&#8217;s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index &#8805; 27 kg&#47;m</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in diabetes and metabolism, neuropathic pain and other indications.  For additional information, please visit www.lexpharma.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Safe Harbor Statement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">clinical development of sotagliflozin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> and the clinical development and therapeutic and commercial potential of sotagliflozin. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s financial position, long term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">the risk that the FDA and other regulatory authorities may not grant regulatory approval of sotagliflozin, and the risk that such regulatory approvals, if granted, may have significant limitations on the approved use of sotagliflozin. As a result, sotagliflozin may never be successfully commercialized. Other risks include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Chas Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Executive Director, Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(281) 863-3421</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">cschultz&#64;lexpharma.com</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20201116.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20201116" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20201116">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201116_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201116_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201116_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20201116_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lxrx-20201116_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201116.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lxrx-20201116_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201116.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended" id="i38f85a1cea854b09ba60beba2c914db2_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lxrx-20201116_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_9663e4d9-e4d4-4d09-a0eb-998f0a6eb300_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d53deb7c-a2bc-48fa-9bc8-cbc65f695159_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7dde5214-c1e9-43c5-ab00-df88522c736f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_40eae039-3db4-478c-aeba-fd9e24fdeb46_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_63384d8f-ee4d-4d5e-b57e-1f1729130b6d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_642c581e-3d71-420d-9ba1-012fa20fcd0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_27b62f65-c042-4735-aefd-a53042f8084e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5a7376db-f42a-47a8-b8b4-c02da8b8edae_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_de4e0b1b-6b02-4617-9e84-d0844a2aa1bc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_189fdf02-02a6-4b38-ad4b-6d5a42db707f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f3fb49e5-c286-4381-8789-79a446eb36ff_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e645b643-efcd-4a9b-9721-e80e2078abcf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cfc64e53-7f8e-4d71-ad86-c6388b2cc987_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cb384a31-f734-4b32-9ab1-1f82554c7323_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a4ec2767-8077-460b-ae7a-40f3989935af_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d2b3804a-a4c0-4bbc-8f5b-60575b024566_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_16980b0f-56c6-485a-8c5f-70b2b84bd4af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_331bef45-ee27-4791-9636-13404ecaffb5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_818b08e0-7118-45d2-99d6-7a3b77ea13f2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_63dba613-3e80-4723-aabd-18c935902092_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f238605c-38a3-400f-9833-a673a1548c5c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c4bf8355-7050-458f-80f7-5b3c98d0fb4b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lxrx-20201116_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:8618c21b-0aeb-4445-973d-b901ca0ab825,g:842587ec-a728-49e2-a546-7cf5aefcb620-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20201116.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_61794d1f-b316-41e4-80a5-c211c2fe6e2a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_DocumentType_61794d1f-b316-41e4-80a5-c211c2fe6e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4f1e666a-b575-4eda-9b10-709cbe6ba0cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_DocumentPeriodEndDate_4f1e666a-b575-4eda-9b10-709cbe6ba0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5a4cea33-abd3-4cb9-849a-a192ad70c86e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityRegistrantName_5a4cea33-abd3-4cb9-849a-a192ad70c86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7c495365-d089-4738-bc89-851e6d162fab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7c495365-d089-4738-bc89-851e6d162fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5eae9eb0-8639-4289-bbaf-69313b491857" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityFileNumber_5eae9eb0-8639-4289-bbaf-69313b491857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_08fc4594-97d9-4099-b88a-8a946a4cc4c2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityTaxIdentificationNumber_08fc4594-97d9-4099-b88a-8a946a4cc4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e56c3634-3cb2-4998-9a4d-dcda9bee0b19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityAddressAddressLine1_e56c3634-3cb2-4998-9a4d-dcda9bee0b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ebc64301-2edc-47c5-92ef-9609a30a452c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityAddressCityOrTown_ebc64301-2edc-47c5-92ef-9609a30a452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0582c541-9bc4-4798-b8e6-490cfed7f65b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityAddressStateOrProvince_0582c541-9bc4-4798-b8e6-490cfed7f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e1237c67-a1c7-4ecf-9ed3-cbde25fb68ca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityAddressPostalZipCode_e1237c67-a1c7-4ecf-9ed3-cbde25fb68ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_41c2783a-fd50-4ba7-afc7-680a35e8fe22" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_CityAreaCode_41c2783a-fd50-4ba7-afc7-680a35e8fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_048985c6-a6e2-4aca-890d-33d98d389b24" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_LocalPhoneNumber_048985c6-a6e2-4aca-890d-33d98d389b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6085e3e6-b304-45b9-97c6-fbd481a4d789" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_Security12bTitle_6085e3e6-b304-45b9-97c6-fbd481a4d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6b94d032-9bd8-4015-bcaa-8f705104ffe3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_TradingSymbol_6b94d032-9bd8-4015-bcaa-8f705104ffe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_27208cb7-eb9b-4b91-94f7-73d4d1fc095d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_SecurityExchangeName_27208cb7-eb9b-4b91-94f7-73d4d1fc095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7aeb27a6-6202-4dbb-8d01-83d3bb3c343f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_WrittenCommunications_7aeb27a6-6202-4dbb-8d01-83d3bb3c343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c4c3f7fc-81b9-4f70-a3d3-a3a890988c1c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_SolicitingMaterial_c4c3f7fc-81b9-4f70-a3d3-a3a890988c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_267b9f95-722a-4175-a31c-8242fb7890ae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_PreCommencementTenderOffer_267b9f95-722a-4175-a31c-8242fb7890ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e95fd409-523b-47c5-b677-82d72d0c5ca2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e95fd409-523b-47c5-b677-82d72d0c5ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7840a5b0-39e2-4c59-96d9-a2fcf12c1e75" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityEmergingGrowthCompany_7840a5b0-39e2-4c59-96d9-a2fcf12c1e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_23ec5f58-133d-4eb2-b8a7-3240b72e56dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_EntityCentralIndexKey_23ec5f58-133d-4eb2-b8a7-3240b72e56dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7e9d9155-69be-4c3f-b875-c33c2fc226ae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0d565e-4b47-4a2f-b8fd-092e38b4cd96" xlink:to="loc_dei_AmendmentFlag_7e9d9155-69be-4c3f-b875-c33c2fc226ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>lxrx-20201116_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20201116.xsd" xlink:type="simple"/>
    <context id="i270954990545440a902712dda84cdeec_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV80L2ZyYWc6YWZhYTBjN2M5YTFhNDVkY2ExYzYyMDcyYTA5Zjk1Y2IvdGFibGU6ZDk3ZDVlNTVjMzc5NGRlYWIyZThmMWM5ZGE3OGVlNmIvdGFibGVyYW5nZTpkOTdkNWU1NWMzNzk0ZGVhYjJlOGYxYzlkYTc4ZWU2Yl8wLTEtMS0xLTA_0867a43a-b53a-492d-a86a-4c73e3d42542">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV80L2ZyYWc6YWZhYTBjN2M5YTFhNDVkY2ExYzYyMDcyYTA5Zjk1Y2IvdGFibGU6ZDk3ZDVlNTVjMzc5NGRlYWIyZThmMWM5ZGE3OGVlNmIvdGFibGVyYW5nZTpkOTdkNWU1NWMzNzk0ZGVhYjJlOGYxYzlkYTc4ZWU2Yl8xLTEtMS0xLTA_a86286a4-3764-46dd-a8b1-4576c790ff8b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjkx_560d42dd-6488-48d6-b041-da9b37ee7ac9">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8yNjY_ba3f57e2-8ae0-488a-8721-228fe7cba944">2020-11-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjky_c1ede87c-7b6a-497b-8160-af3c5b590da5">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTAtMS0xLTA_d2bb0705-c6f9-46e1-a344-2f749130d75f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTEtMS0xLTA_6c6d9301-ef79-41ab-99cf-6b48bffdc2c9">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6ZmYzMGE4MDUzNGRjNGJlMjkyMTk3MjZkY2JhMjM1MjgvdGFibGVyYW5nZTpmZjMwYTgwNTM0ZGM0YmUyOTIxOTcyNmRjYmEyMzUyOF8wLTItMS0xLTA_9f0c9b50-61df-4329-8cea-f5a4e8428575">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg1_ebd96192-3e18-4b07-b6b0-dab37ca09b77">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg2_9ec94ff4-b6c0-4fa6-bbb4-b94fa4977cd4">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjkz_1617e7d5-f86d-434b-b1ae-a49b233cc8b5">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV80MDk_d3b7ee8c-c1a1-45d2-a5cd-d39f187e1204">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV80Njg_3c94bedd-654e-4e0b-b8e9-27d123e4f18b">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjk0_b0dbb7ca-e455-4322-9b94-d3983e7ece3c">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTAtMS0xLTA_ec20cf52-4154-4888-a186-dcd2b359f49a">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTEtMS0xLTA_44694ecd-aada-45ed-92b5-a092c38aec01">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGFibGU6YjVkMTQ0NmUyZjA4NGY5YWFlMGYzZTEzNWNlM2E0YWEvdGFibGVyYW5nZTpiNWQxNDQ2ZTJmMDg0ZjlhYWUwZjNlMTM1Y2UzYTRhYV8xLTItMS0xLTA_20932a4f-fb53-425a-8b57-25df14ae579a">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg3_7d6b4e36-2548-4150-bf02-3e49550d24ac">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjgw_f41177fe-3143-4f33-8989-5e1e77d5e5af">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg0_27abc27c-9d56-4670-85e7-075e454c1cb7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjg5_e55c2392-4c60-4978-805c-9a205b5730ec">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i270954990545440a902712dda84cdeec_D20201116-20201116"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1M2JkZTdmNzFkZjQyNzI5MGU0NTBmNTI3MTQ2ZDM5L3NlYzo0NTNiZGU3ZjcxZGY0MjcyOTBlNDUwZjUyNzE0NmQzOV8xL2ZyYWc6YjNjODljMjIyMGVkNDk1ODg2MmRhNTI0ODlhZmYwNjkvdGV4dHJlZ2lvbjpiM2M4OWMyMjIwZWQ0OTU4ODYyZGE1MjQ4OWFmZjA2OV8xNjgy_5fb20628-e5b2-46c6-ac39-e9bbbfd91e22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139851898772456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 16,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ME9C1<N(V%(:OMT^A87K1SB2Q90B0'<(,(<DVL]DL#;39::<7PA98$UER93G
MV_?(@,UNS3&YB27;Y^?3.=(O*X.5-J]9S+DEZT2J[+H56YM^]+PLC'G"L@N=
M<@5/%MHDS$+7++TL-9Q%15 BO<#WNU["A&H-!\6]B1D.=&ZE4'QB2)8G"3.;
M&R[UZKI%6_L;SV(96W?#&PY2MN13;O]()P9Z7JD2B82K3&A%#%]<MT;TXTW0
M<0'%&W\*OLH.VL0-9:[UJ^L\1-<MWQ%QR4/K)!A<WOB82^F4@./?G6BK_$T7
M>-C>J]\7@X?!S%G&QUJ^B,C&UZU^BT1\P7)IG_7J-[X;T*73"[7,BK]DM7VW
MTVF1,,^L3G;!0) (M;VR]2X1!P%M>B0@V 4$!??VAPK*6V;9<&#TBACW-JBY
M1C'4(AK@A')5F5H#3P7$V>%8OW$S\"Q(N1M>N N[V88%1\*>]-L%H=TS$OB!
M_WVX!P0E1E!B!(5>&\,@?X_FF350J'\0R78IV2XD.T<D;W68P_2Q9+9)>=T(
M\?#^^6<$HE-"=$Z#F' C=$3N5$2@3K4\N-(^XS]]^-"0\\N2[1)5O%-6V UY
MYDOAL@Z03RRI)<-U'OE:A+# )C&#91+RW(J0R>R,/*CP N'LEIS=4SA!39M4
M&^96\QF96D@CT8:,=:ZLV< UJH7'Q6_O$,)>2=@[A?!>2$Z>\F1>OZ)P#=_W
MS]L^I13AZ9<\_5-X9FQ-'B*8?6(!%2E,\#@=KMCKGON=7H=VKQ"\JQ+OZA2\
M4109GL$\V37(([Q'OJK:*N**_;[ODQD/8Z6E7D(E- C"HI,P'1%@ZE<NZ;\+
M>>QZ,/EF>J5JW1.7F\6<O&@=2::B# ,\L''Z+L!R>4R,?A/JQS3L*''-V3<,
MK;)V&KP+;:(SRR3Y2Z1'UVR#8J_7[F/KA%9[!,5=OJCC"#YGCJ/@ @$.4NT3
M%+?W1PV>"1:J%68A#2+];AL\Q,<V!UKM#A2W]9FP8&=Z06CPR_Q7,N5A;B!;
MM5BXTE@G"7C/U.KP]8RDS) W)G-.?O8O?!]-7[5%4-S&9X9%0BW)=)/,M:QE
MQ 4>OSVCL[W:"BCNX_L\D;MU&#.UY$=WU0:AI]'T=O0[QE1M!Q1W[Q< LEP1
M5XA<[?:"K)8)%UK OHX::K4%4-RQIUJ*4%A7LR_@5$:P^JKA*DT\067P >[(
M$\//0T@/!ZO<?C5R%<$GZ=?%HGXI-N@UDE7.'N N_#^RARS+@:P1$)=M!#SX
M=#_)W^\2;I:NGI] P<9NLJ5,U?I%@V C6F7O >[..[0QI,V O3Y QM;D,Z^'
MPJ7 5JG?#?I!@)%5?A_@5CV"4D9%.>\E6];RX )'D^0=' ;=P?H+<V7)B.0+
M$/(O>F#69GM6W7:L3HOSX5Q;.&T6S1C.]]RX%^#Y0FN[[[@C9_D?@^%_4$L#
M!!0    ( ,DZ<5&#J:4#U $  #(&   -    >&PO<W1Y;&5S+GAM;-55VXK4
M0!#]E:8_P)Y$=D%) BHL""H+.P^^=I)*TM W.Y4QV:^W.YW;N RH#Z(ODSJG
MJD^=OD[6XR3AJ0- ,BJI^YQVB/8M8WW5@>+]*V-!^TQCG.+HH6M9;QWPN@^#
ME&3IZ73/%!>:%ID>U(/"GE1FT)C3$V5%UAB],Z]I)'PI5T N7.;T Y>B=&*N
MY4K(*=)I("HCC2/HK4!.D\#TSS&=1!1<+CI*:.,"R6*'^%LNY3\E5M1[**3<
M#*8T$D5F.2(X_>#!7#R3+U)DB<^3]0Y;QZ<DO:/[@/GCFY3&U>"V-@E=J2*3
MT 0[3K1=^**Q+"01C?)!+7AK-)\]K".6P,M6(.53V,*OS97VV)"X%Q_KL TD
M3'4-O:$EC#(1!/VC6M0^R-[]D2RQXF+P_>!GHV?\;3 (CPX:,<YX;+;^M]23
MV^K<6CF]DZ+5"N+<?[EAD?%U'.F,$\^^6S@IE2? 47(!AZ(Z,M\=MV<8<3U-
M8W/;<_H?>OZ[Z]R"!L?ET;0_^O_R*O^.8[;<GL,5O;J@&TO"0YC3+^%]E;L'
M4@Y"HM +ZD1=@WYQ3[T\\M(_X%?ZOKZ&A@\2SULRIWO\&6HQJ#=;U6-8EZ5J
MCS^%]RBYGQON_Q+%#U!+ P04    " #).G%1EXJ[',     3 @  "P   %]R
M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:
MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$
MVV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_
M,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH
M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,DZ<5&JQ"(6,P$  "("
M   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-
MB??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!
MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$
M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ R3IQ4660>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( ,DZ<5%Z9I64[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,DZ<5&97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ R3IQ43P4#KTU!   /1   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,DZ<5&#J:4#U $
M #(&   -              "  7@,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  .\2      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20201116.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20201116.htm">lxrx-20201116.htm</File>
    <File>lxrx-20201116.xsd</File>
    <File>lxrx-20201116_cal.xml</File>
    <File>lxrx-20201116_def.xml</File>
    <File>lxrx-20201116_lab.xml</File>
    <File>lxrx-20201116_pre.xml</File>
    <File>pressreleaseahasotagli.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20201116.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20201116_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20201116_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20201116.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20201116_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20201116_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20201116.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20201116",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20201116.htm",
      "contextRef": "i270954990545440a902712dda84cdeec_D20201116-20201116",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20201116.htm",
      "contextRef": "i270954990545440a902712dda84cdeec_D20201116-20201116",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001062822-20-000073-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-20-000073-xbrl.zip
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M&EZ,O$CRT:= IE3,VY^]+F:O2JFX^<ZQBPY9_)H4M?-WI:SM>%Y@1D,SGY4
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M'^"1/ZQ5ZKAO2ML78EQIPBF<DMN\X8[W)^:P7]O3YM#Q3I^#%5- AVOQX*;
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MQEV:Z]MX+NVI4QU07P240&VD@I1' D8A]J!F2&,4,BYD:UEN.AZ;)!_O72K
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MQZX/O7=WO>5VX+ZZ/JC=CKK!KDG"F[Q?V*,WS];OQ,N'>K]Y]G]02P,$%
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MX_)G90_!Q]*3,67=O@"8A8[ X>8R"3RJ)K4-0>6%!VC?!1Q5 %EE+ZG&:!;
M1IP#2Y!5@D6Q7/Y^T&Z9V@==+$$<S1UI&>99WP4R!\084E\0J]&X<"Q V[R4
M9C(NC""9&G\VR!3;4H8R'(O7?R$N=K(JK:0-HL;1I28M(MQ%*J-9E6\K>+ E
M$&CMON"M0;S)A)J\\$:MVB,R^EL846X?R^$&=PCGT0:W_9-F$]%%/H%^!XL<
M8'_%7:7$HN*;VP!7U,90F9;BS16">%^M-KFZ*_$L.#+4MD06:21)AX KU:9E
MJ,@_>M*TC\CJU[MN#)QYO\4F5=1CH($KCA;3&AM%T?3QV$F*MV[0TYR9K^4
M:W6I06"6BC.COIUA7MEJUG_++@?$#8I84Q=X Z)C;OSNM/#&[]8!*<1$>FG_
ME"YJ$Q!@9,;TP1>\# T2N1,0IDEO\PR)2([YK<#2""BKAZT127TNEH0H7$:-
MDCM)]]!]E8%8NA&FE9][/).WSHNIBA58VNG71CGF\)R'2U.>NPV/O-M ?]X$
M$]Z+ (/%T@W_#UQ*LG_KIK?_%&X,K%[="=8_ALX,#/;/QT_M(+OL]=1>]EH#
M!Z=#1=M"T=4E07:9*KK!"^K\@BK="-,\^8Z2YT,O\B^KU3XTX=OM_=8.V^]W
MZIUN^UY_D^COI=>)C-Z_>M'O'A5J9D\SJ.R:OV9&?U?MS?\#4$L! A0#%
M  @ R3IQ4:FXL_M^$P  FX(  !$              ( !     &QX<G@M,C R
M,#$Q,38N:'1M4$L! A0#%     @ R3IQ44.!N+") @  >@D  !$
M     ( !K1,  &QX<G@M,C R,#$Q,38N>'-D4$L! A0#%     @ R3IQ4?[L
M=UB# 0  R (  !4              ( !918  &QX<G@M,C R,#$Q,39?8V%L
M+GAM;%!+ 0(4 Q0    ( ,DZ<5'WNVXD!P(  &T&   5              "
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=9VQI+FAT;5!+!08     !P ' -(!  #B00     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
